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ABSTRACT 
Objective: To undertake a systematic review and meta-analysis of studies that investigated prognostic 
factors and survival in patients with progressive supranuclear palsy (PSP) and multiple system 
atrophy (MSA).  
Methods: Publications of at least 10 patients with a likely or confirmed diagnosis of PSP or MSA 
were eligible for inclusion. Methodological quality was rated using a modified version of the Quality 
in Prognostic Studies tool. For frequently examined prognostic factors, hazard ratios (HR) derived by 
univariate and multivariate analysis were pooled in separate subgroups; other results were synthesised 
narratively and HRs could not be reported here.  
Results: Thirty-seven studies presenting findings on 6193 patients (1911 PSP, 4282 MSA) fulfilled 
the inclusion criteria. We identified the following variables as unfavourable predictors of survival: In 
PSP: PSP-Richardson’s phenotype (univariate HR: 2.53; 95%CIs: 1.69, 3.78), early dysphagia and 
early cognitive symptoms. In MSA: severe dysautonomia and early development of combined 
autonomic and motor features but not MSA phenotype (multivariate HR: 1.22; 95%CIs: 0.83, 1.80). 
  
In PSP and MSA survival was predicted by early falls (multivariate HR: 2.32; 95%CIs: 1.94, 2.77), 
the NNIPPS Parkinson plus score and the Clinical Global Impression disease severity score but not 
sex (multivariate HR: 0.93; 95%CIs: 0.67, 1.28). There was conflicting evidence regarding the 
prognostic effect of age at onset and stridor.   
Conclusion: Several clinical variables were strongly associated with shorter survival in PSP and 
MSA. Results on most prognostic factors were consistent across methodologically diverse studies; 
however, the lack of commonality of prognostic factors investigated is a significant limitation.  
Key words: Progressive supranuclear palsy, multiple system atrophy, survival, prognosis, prognostic 
factors, systematic review, meta-analysis 
PROSPERO registration number: CRD42016032968. Registered on 21st of January 2016   
 
ABBREVIATIONS 
MSA = multiple system atrophy; MSA-C = MSA-Cerebellar; MSA-P = MSA-Parkinsonism;  
NNIPPS = Neuroprotection and Natural History in Parkinson Plus Syndromes; PSP = progressive 
supranuclar palsy; PSP-P = PSP-Parkinsonism; PSP-RS = PSP-Richardson’s syndrome  
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INTRODUCTION 
 
Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare, debilitating adult-
onset neurodegenerative conditions. Their estimated prevalence is 2-7 per 100 000.[1-4] PSP is 
characterised by the accumulation of abnormally phosphorylated tau protein in the basal ganglia, 
frontal lobe and brainstem, whereas MSA is characterised by the accumulation of alpha synuclein 
positive glial cytoplasmic inclusion bodies [5] affecting the basal ganglia, cerebellum, pons and 
substantia nigra.[6] PSP can be divided into PSP-Parkinsonism (PSP-P) and PSP-Richardson’s 
syndrome (PSP-RS) [7] and MSA can be classified into MSA-Cerebellar (MSA-C) and MSA-
Parkinsonism (MSA-P) subtypes.[8] Diagnostic criteria have been proposed for the clinical diagnosis 
of PSP and MSA;[9-11] however, pathological brain examination at autopsy remains the gold 
standard for diagnostic classification.  
 
Prognosis of PSP and MSA is poor. The mean survival after diagnosis is only 3-4 years.[12, 13] To 
date, there are no narrative or systematic reviews on prognostic factors in PSP and MSA. Predictors of 
survival were investigated in numerous studies, including several prospective multicentre studies,[14-
16] single centre clinical studies,[17, 18] post-mortem studies [19, 20] and a meta-analysis of 
pathologically confirmed case studies.[21] Researching prognosis of PSP and MSA is challenging in 
view of their rarity, insidious onset and heterogeneity of clinical presentation. Therefore, studies are 
frequently underpowered and at risk of diagnostic ascertainment bias or selection bias depending on 
whether participants were diagnosed clinically or recruited post-mortem from a brain-bank. A 
systematic review and meta-analysis is therefore desirable to increase power and to investigate and 
quantify the methodological and statistical heterogeneity across studies. Here, we sought to 
summarise, synthesise and contrast published studies that investigated the association between 
potential prognostic factors and survival.  
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METHODS 
 
Study registration and inclusion criteria 
This work adheres to the preferred reporting items for systematic reviews and meta-analyses 
standards (PRISMA).[22] A protocol was registered with PROSPERO, registration number: 
CRD42016032968. Studies of any design, reporting on one or more potential prognostic factors 
predicting survival in PSP and/or MSA patients were eligible for inclusion. Participants were patients 
identified by study authors as having a likely or confirmed diagnosis of PSP, MSA, Steele-
Richardson-Olszewski syndrome, striatonigral degeneration, olivopontocerebellar atrophy or Shy-
Drager syndrome. The following prognostic factors were considered: demographic variables, 
symptoms, clinical signs, disease phenotypes, rating scales, biomarkers and imaging findings. 
Exclusion criteria were as follows: 1) meeting abstracts or conference proceedings, 2) articles in 
languages other than English, German or French, 3) case studies or studies including fewer than 10 
participants and 4) statistical analysis other than time-to-event analysis. Studies were also eligible if 
they investigated the difference in survival between PSP and MSA.  
 
Identification of studies 
The electronic databases of Medline, Embase, CINAHL and the Cochrane library were searched from 
inception until December 2015/January 2016 for studies conducted on humans; no language 
restrictions were employed. The search strategy included a combination of keywords and MeSH terms 
(see online protocol). For studies retrieved in full-text, hand searching of reference lists and citation 
searches were performed. Grey literature searches were performed in several grey literature databases.  
 
Methodological quality assessment and data extraction 
Studies were individually graded for risk of bias by one reviewer (SAG), using a modified version of 
the Quality in Prognostic Studies tool.[23] A random sample of five papers was reviewed by a second 
reviewer (RAS) to check that there was no systematic bias in the method followed by the primary 
reviewer. The study’s risk of bias was rated as low, moderate or high on 14 items according to pre-
specified criteria (supplementary table 1). A summary score was not calculated in keeping with 
recommendations by the Cochrane Collaboration.[24] One reviewer (SAG) extracted data from all 
included studies using a pre-specified data extraction sheet and a second reviewer independently 
extracted results reported by studies included in the main text; there were no disagreements. 
For three studies, corresponding authors were contacted to provide clarification on missing data; 
however, none could provide these.  
 
Statistical analysis  
Hazard ratios derived by univariate and multivariate analysis were pooled in separate subgroups in 
generic inverse variance meta-analyses in Review Manager 5.3 using a random effects model. Hazard 
ratios adjusted for age and/or sex were included in the subgroup containing hazard ratios derived by 
multivariate analysis. The meta-analytic summary includes the pooled estimate for each subgroup and 
its 95% confidence intervals. Statistical heterogeneity was quantified using the I2 test; I2 represents the 
percentage of heterogeneity that cannot be attributed to chance. Where only Kaplan-Meier curves 
were reported by studies, methods by Tierney and collaborators [25]  were used to extract hazard 
ratios from published Kaplan-Meier curves (12 prognostic factors, 8 studies). Kaplan-Meier curves 
were inspected for severe violations of the proportional hazards assumption prior to data extraction. 
Anonymised patient data published by Birdi and colleagues [26] were analysed in SPSS version 23.0 
with univariate Cox regression. Sensitivity analysis was undertaken to gauge the effect of including 
studies at high risk of diagnostic ascertainment bias in meta-analysis. Results of such studies were 
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graphically displayed in forest plots but were not weighted in the pooled effect estimate. Publication 
bias was examined for by inspecting funnel plots for the two most commonly reported prognostic 
factors. Results were synthesised narratively where heterogeneity across study definitions of a 
prognostic factor did not allow meta-analysis. A p-value <0.05 was considered statistically 
significant.  
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RESULTS 
 
The search yielded the following results: Medline: 934 results, Embase: 1420 results, CINAHL: 155 
results and the Cochrane library: 38 results. The selection process is illustrated in figure 1. A total of 
40 publications describing 37 studies, investigating 34 distinct patient cohorts were therefore included 
in narrative synthesis, of which 22 studies were also included in one or more meta-analyses. Meta-
analysis was possible for seven prognostic factors: sex, age at disease onset, MSA phenotype, PSP 
phenotype, onset of falls, levodopa response and orthostatic hypotension.  
Eleven studies recruited PSP patients,[12, 19, 26-34] 20 studies recruited MSA patients [15-18, 21, 
35-51]  and six studies recruited both PSP and MSA patients.[3, 9, 13, 14, 20, 52, 53] Seven studies 
reported pathological confirmation of diagnosis in 100% of patients. Studies reported on a total of 
6193 patients including 4282 MSA patients of whom 759 had a pathologically confirmed diagnosis 
and 614 were included in post-mortem studies. There were 1911 PSP patients of whom 415 had a 
pathologically confirmed diagnosis and 250 were included in post-mortem studies. The mean age at 
disease onset ranged from 61.0 to 67.2 years in PSP and from 54.0 to 64.5 years in MSA and the 
proportion of male and female patients was approximately equal. The study characteristics can be 
found in supplementary table 2 and the risk of bias ratings in supplementary table 3; differences in 
symptom profile between clinical and post-mortem studies are reported in supplementary table 4. 
 
Overall survival  
The cumulative survival in PSP and MSA is shown in figure 2 and 3 respectively (supplementary 
figures 1 and 2 for colour images). Ten studies reported on patients that survived beyond 15 years 
after disease onset, of which three studies reported pathological confirmation of diagnosis in 100% of 
patients. Median survival from disease onset ranged from 5.3 to 10.2 years. One study [43] reported a 
median survival of 13 years but was judged to be at high risk of diagnostic ascertainment bias. Studies 
on MSA patients generally reported higher median survival than studies on PSP patients; however, 
studies including both MSA and PSP patients found similar survival between PSP and MSA. In the 
Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) study PSP was 
associated with longer survival only when adjusted for dysautonomia, disease severity, disease 
duration and the Schwab and England Activities of Daily Living scale in multivariate analysis.[14]  
 
Demographic factors 
Table 1 summarises the evidence on frequently examined prognostic factors. Ten studies (n=2728) 
comparing survival between male and female patients were combined in meta-analysis (figure 4). The 
pooled hazard ratio in the subgroup containing hazard ratios derived by univariate analysis was 1.05 
(0.95, 1.18), I2=32% and n=2102, whereas the pooled hazard ratio in the subgroup containing hazard 
ratios derived by multivariate analysis was 0.93 (0.67, 1.28), I2=34% and n=675. There were no 
significant differences between subgroups (p=0.45). Five studies only reported p-values but not 
hazard ratios and could not be included in meta-analysis,[17, 28, 30, 38, 53] one of which reported a 
significant effect of sex on survival in multivariate analysis.[28]  
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 Negative prognostic factor  Total 
nr of 
studies 
Meta-analysis 
Pooled HR (95% confidence intervals) 
Narrative synthesis 
 
Univariate HR I2 Multivariate HR* I2 Nr of 
studies 
reporting a 
significant 
effect on 
survival  
HRs (95% confidence intervals) 
or other effect measures of 
studies reporting a significant 
effect on survival of the negative 
prognostic factor 
UV = univariate 
MV = multivariate 
PSP PSP-RS (vs PSP-P phenotype) 4 2.53 (1.69, 3.78) 18% 2.37 (1.21, 4.64) n=1  
Early development of dysphagia 4  4 MV: 3.91 (1.39, 11.0) 
MV: 2.84 (1.51, 5.34) 
MV: 2.3 (1, 5.3) 
1.9 year difference median survival 
Early development of cognitive 
symptoms 
4  2 MV: 3.6 (1.6, 8.2) 
MV: 1.99 (1.17, 3.38) 
Vertical supranuclear gaze palsy 5  2 MV: 2.74 (1.52, 4.94) 
UV: 1.12 (1.10, 1.31)  
MSA MSA-P (vs MSA-C phenotype) 8 1.12 (0.97, 1.29) 9% 1.22 (0.83, 1.80) 19%  
Severe dysautonomia: 
-Mild vs severe (2 studies) 
-CGI dysautonomia score (1 
study) 
-CASS (2 studies) 
5  5 2.3 year difference median survival  
3.5 year difference median survival 
MV: 1.41 (1.19, 1.67) 
MV: 1.07 (1.02, 1.11) 
MV: 2.8 (1.01, 9.26) 
Development of dysautonomia 
within 1, 2 and 2.5 years of MSA 
onset 
3  3 UV: 1.24 (1.04, 1.49) 
MV: 6.0 (3.1, 11.7) 
MV: 3.4 (1.61, 7.15) 
Combined motor and autonomic 
symptoms within 3 years of MSA 
onset 
2  2 UV: 2.65 (1.42, 4.93) 
3 year difference median survival 
Orthostatic hypotension 2 1.24 (1.04, 1.49) 0% 1.29 (1.07, 1.56) 0%  
Dysautonomia present at MSA 
onset 
5  0 NA 
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Bladder symptoms 5  Conflicting results and heterogeneous definitions 
of prognostic factor 
Stridor 6  2 MV comparing untreated stridor to 
no stridor: 3.0 (1.63, 5.53) 
Reduced survival after 6 years as 
evident from Kaplan Meier curve 
PSP 
and 
MSA 
Male sex 10 1.05 (0.95, 1.18) 32% 0.93 (0.67, 1.28) 34%  
Age at disease onset: 
-above median age (9 studies) 
-per year increase (6 studies) 
14  
1.92 (1.50, 2.44) 
1.01 (1.0, 1.02) 
 
0% 
23% 
 
1.75 (1.32, 2.32) 
1.10 (0.98, 1.23) 
 
63% 
68% 
 
Early onset of falls 6 1.62 (0.55, 4.77) 87% 2.32 (1.94, 2.77) 0%  
Levodopa response 4 0.87 (0.73, 1.02) 1% 0.60 (0.31, 1.14) n=1  
NNIPPS Parkinson plus score 1  1 MV: 1.01 (1.01, 1.02) 
Clinical Global Impression 
disease severity score 
1  1 MV: 1.28 (1.09, 1.51) 
Hoehn and Yahr staging scale: 
-Overall score (2 studies) 
-Stage 5 (1 study) 
3  1 MV stage 5: 12.45 (1.93, 80.93) 
PSP Rating Scale 2  2 No effect sizes reported 
Unified MSA Rating Scale: 
-overall score 
-activities of daily living sub-
score 
2  1  Activities of daily living sub-score 
MV: 1.04 (1.01, 1.07) 
Northwestern University 
Disability Score 
1  0 NA 
Shorter interval between disease 
onset and first clinical milestone 
2  2 UV: 3.4 (1.4, 8.3) 
PSP MV: 1.25 (1.11, 1.4) 
MSA MV: 1.72 (1.47, 2.04) 
 
Table 1. Summary of evidence on frequently examined prognostic factors predicting survival. A more detailed breakdown of results, including non-
significant results, is available in the supplementary material. *Refers to hazard ratio derived by pooling hazard ratios calculated by multivariate analysis in 
individual studies. CASS = Composite Autonomic Scoring Scale; HR = hazard ratio; MSA-C = MSA-Cerebellar; MSA-P = MSA-Parkinsonism; MV = 
multivariate analysis; NNIPPS = Neuroprotection and Natural History in Parkinson Plus Syndromes; PSP-P = PSP-Parkinsonism; PSP-RS = PSP-
Richardson’s; UV = univariate analysis
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Fourteen studies (n=2954) investigating the effect of age at disease onset on survival were combined 
in meta-analysis (supplementary figure 3). Nine studies compared the survival of patients aged above 
and below the median age at disease onset reported by each study. The pooled hazard ratio in the 
subgroup containing hazard ratios derived by univariate analysis was 1.92 (1.50, 2.44), I2=0% and 
n=288, and the pooled hazard ratio in the subgroup containing hazard ratios derived by multivariate 
analysis was 1.75 (1.32, 2.32), I2=63% and n=973. Subgroups were not significantly different 
(p=0.74). Six studies reported the prognostic effect of age at disease onset per year increase, the 
pooled hazard ratio in the subgroup containing hazard ratios derived by univariate analysis was 1.01 
(1.0, 1.02), I2 =23% and n=1669, and the pooled hazard ratio in the subgroup containing hazard ratios 
derived by multivariate analysis was 1.10 (0.98, 1.23), I2 =68% and n=260. Six studies only reported 
p-values but not hazard ratios and could not be included in meta-analysis,[10, 17, 28, 32, 50, 53] of 
which two studies reported a significant effect of age at disease onset on survival.[17, 28]  
 
Disease phenotypes 
Eight studies (n=1572) comparing survival of the MSA-P and MSA-C phenotypes were combined in 
meta-analysis (figure 5). The pooled hazard ratio in the subgroup containing hazard ratios derived by 
univariate analysis was 1.12 (0.97, 1.29), I2=9% and n=1310, and the pooled hazard ratio in the 
subgroup containing hazard ratios derived by multivariate analysis was 1.22 (0.83, 1.80), I2=19% and 
n=311. Subgroups were not significantly different (p=0.67). Four studies only reported p-values but 
not hazard ratios and could not be included in meta-analysis, none of which reported a significant 
effect of MSA phenotype on survival.[17, 41, 50, 53]  
 
Four studies (n=268) comparing survival of the PSP-RS phenotype to the PSP-P phenotype were 
combined in meta-analysis (figure 6). The pooled hazard ratio in the subgroup containing hazard 
ratios derived by univariate analysis was 2.53 (1.69, 3.78), I2=18% and n=268; one study (n=110) 
reported a hazard ratio derived by multivariate analysis of 2.37 (1.21, 4.64). One study only reported 
the difference in median survival (PSP-RS 6.8 years vs PSP-P 10.9 years).[27]  
 
Onset of falls 
Six studies (n=1116) investigating the effect of falls within 1-3 years of disease onset on survival 
were combined in meta-analysis (figure 7). The pooled hazard ratio in the subgroup containing hazard 
ratios derived by univariate analysis was 1.62 (0.55, 4.77), I2=87% and n=777. The pooled hazard 
ratio in the subgroup containing hazard ratios derived by multivariate analysis was 2.32 (1.94, 2.77), 
I2=0% and n=1073. The high statistical heterogeneity in the univariate subgroup is almost exclusively 
due to Figueroa 2014,[35] who found early falls to predict shorter survival in multivariate but not 
univariate analysis. Subgroups were not significantly different (p=0.52). One study only reported the 
difference in median survival (early falls 5.2 years vs late falls 6.8 years).[30]  
 
Levodopa response 
Four studies (n=1147) investigating the effect of levodopa response on survival were combined in 
meta-analysis (supplementary figure 4). The pooled hazard ratio in the subgroup containing hazard 
ratios derived by univariate analysis was 0.87 (0.73, 1.02), I2 = 1% and n=960. One study (n=187) 
reported a hazard ratio derived by multivariate analysis of 0.60 (0.31, 1.14).  
 
Symptoms and signs in MSA  
Severe dysautonomia was found to predict shorter survival in MSA, as two studies comparing 
survival between patients with mild or absent and severe dysautonomia [15, 18] and three studies 
evaluating the Clinical Global Impression Dysautonomia score and/or Composite Autonomic Scoring 
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Scale [14, 18, 35] reported a significant effect on survival. Development of dysautonomia within 1, 2 
or 2.5 years of MSA onset and the development of combined autonomic and motor features within 3 
years of MSA onset predicted shorter survival in three studies [18, 20, 46] and two studies [17, 41] 
respectively. However, the presence of dysautonomia at MSA onset did not predict survival in five 
studies.[17, 18, 37, 41, 43] Orthostatic hypotension within 1 year of MSA onset predicted shorter 
survival in a meta-analysis of two studies [18, 35] whilst there was substantial heterogeneity 
regarding the effect of bladder symptoms on survival in five studies.[15, 16, 18, 35, 39] Two studies 
reported significantly reduced survival in the presence of stridor [45, 49] whilst two studies reported 
reduced survival in univariate but not multivariate analysis [18, 39] and two small studies failed to 
reach statistical significance [40, 46] (supplementary table 5).  
 
Symptoms and signs in PSP  
Four studies found early development of dysphagia to predict survival.[12, 29, 30, 33] There is 
conflicting evidence regarding the prognostic effect of vertical supranuclear gaze palsy examined in 
five studies: two studies with overlapping patient cohorts found vertical supranuclear gaze palsy to 
predict survival,[27, 29] two studies failed to show a predictive effect on survival [30, 33] and one 
study reported a predictive effect on survival in univariate but not multivariate analysis.[12] Early 
development of cognitive symptoms or dementia was a predictor of shorter survival in two studies 
[12, 29] but not in two lower quality studies [30, 32] (supplementary table 6).  
 
Disease severity, progression and rating scales  
There is evidence to support the use of the NNIPPS Parkinson plus score and Clinical Global 
Impression disease severity score for prognostic stratification from one study.[9, 14] Stage 5 of the 
Hoehn and Yahr staging scale likely predicts shorter survival as shown by one study [39] but 
otherwise the Hoehn and Yahr staging scale did not predict survival in two studies.[14, 16] Two 
studies found the PSP Rating Scale to predict survival [27, 28] whilst the Northwestern University 
Disability Score did not predict survival in one study.[47] The Unified MSA Rating scale did not 
predict survival in one study [15] although its activities of daily living sub-score predicted survival in 
one study.[16] A shorter interval between disease onset and first clinical milestone also predicted 
shorter survival in two studies [12, 20] (supplementary table 7).  
 
Sensitivity analysis  
Three studies [34, 42, 43]  were excluded from meta-analysis due to high risk of bias ratings in the 
diagnostic certainty domain. Inclusion of the study by Sakushima and colleagues [43] in the meta-
analysis of multivariate hazard ratios comparing survival in MSA-P and MSA-C resulted in MSA-P 
becoming a significant predictor of shorter survival. Otherwise, inclusion of the above studies did not 
affect the overall effect estimates (supplementary table 8).  
 
Reporting bias  
Funnel plots are shown in supplementary figures 5 and 6.  
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DISCUSSION 
 
This is the first systematic review and meta-analysis of studies investigating prognostic factors in PSP 
and MSA. The following variables were identified as unfavourable predictors of survival: PSP-RS 
phenotype, early dysphagia and early cognitive symptoms in PSP; severe dysautonomia and early 
development of combined autonomic and motor features in MSA; and early falls, the NNIPPS 
Parkinson plus score and the Clinical Global Impression disease severity score in PSP and MSA. 
Conversely, MSA phenotype and sex did not predict survival. Survival was similar between PSP and 
MSA patients and between pathologically confirmed cases and clinically probable cases. 
 
Many studies were too small to reach statistical significance; therefore, the increased power gained by 
combining studies in statistical and narrative syntheses yields more conclusive evidence on the 
validity of the above prognostic factors. This review examined the statistical heterogeneity (I2) of 
prognostic results between clinically and methodologically diverse studies. This includes studies on 
PSP and MSA patients and studies on pathologically confirmed cases as well as clinically probable 
cases. I2 values were low (<40%) in all meta-analyses except age at disease onset, indicating that 
differences between the results on prognostic factors across studies were mainly due to chance. 
However, the lack of commonality of prognostic factors investigated is a significant limitation.  
 
The PSP-RS phenotype, compared to the PSP-P phenotype, was highly predictive of shorter survival 
in a meta-analysis of two clinical and two post-mortem studies. Early falls and early development of 
cognitive symptoms, which are characteristic of the PSP-RS phenotype,[7] also predicted shorter 
survival. The latter symptom predicted shorter survival in larger studies of higher quality whereas 
smaller studies failed to show a prognostic effect. The evidence regarding the prognostic effect of 
supranuclear gaze palsy remains inconclusive. Levodopa response, which is characteristic of the  
PSP-P phenotype did not predict longer survival in meta-analysis. This may be due to variation in the 
definition of levodopa response across studies. Early onset of dysphagia, which is common in both 
phenotypes, was predictive of shorter survival.  
 
MSA phenotypes did not predict survival in a meta-analysis of mainly Western studies; this finding 
should be confirmed in Asian countries.[54] Interestingly, symptoms that indicate shorter survival in 
MSA, namely severe dysautonomia and early falls, occur with a similar prevalence in both 
phenotypes.[18]  
 
There has been conflicting evidence on the prognostic effect of dysautonomia in previous studies, 
which may be due to heterogeneous definitions of dysautonomia. This review has identified trends in 
the literature and offers potential explanations to guide future research. Severity of dysautonomia, 
measured with rating scales or subjective impression, predicted survival. Similarly, urinary 
catheterisation, indicating severe impairment, was highly predictive of survival in two studies, 
whereas conflicting evidence was found regarding the effect of incomplete bladder emptying, which 
may range from mild to severe, on survival.  
The development of dysautonomia within a specified period of MSA onset and the time until the 
development of combined motor and autonomic features, but not the presence of dysautonomia at 
MSA onset predicted survival. It can be hypothesised that the first two prognostic factors represent 
the same entity: studies investigating the prognostic effect of development of dysautonomia within a 
specified time of MSA onset may have included many patients presenting with motor onset who 
developed dysautonomia soon after. This hypothesis would be in keeping with a series of five long-
term MSA survivors.[55] Similarly, a shorter interval between disease onset and first clinical 
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milestone predicted shorter survival. This review therefore emphasises the importance of rate of 
progression and severity of MSA symptoms as prognostic indicators.  
 
There was conflicting evidence regarding the prognostic value of age at disease onset and stridor in 
MSA. The high statistical heterogeneity in the meta-analysis of age at disease onset may be due to 
variation in the median age of onset. Stridor was an independent predictor of survival in multivariate 
analysis in one study, which was the only study to control for the effect of stridor treatment on 
survival. The beneficial effect of stridor treatment on survival should be confirmed in a larger cohort 
of patients.  
 
Few studies investigated rating scales thus further research is warranted. The NNIPPS Parkinson plus 
score and the Clinical Global Impression disease severity score were found to predict survival; the 
PSP Rating Scale may predict survival but effect sizes were not reported.  
 
Limitations of primary studies  
The small number of prospective studies and low proportion of pathologically confirmed cases are 
limitations of this review. The risk of diagnostic ascertainment bias was especially high in five 
studies, where PSP or MSA diagnosis was based on the subjective assessment of the treating 
neurologist or on diagnostic criteria that are not internationally accepted. Studies of the latter type 
were not weighted in the meta-analytic summary effect estimates.  
Several studies did not report hazard ratios or Kaplan Meier curves and were therefore not included in 
meta-analysis. However, most p-values reported by studies excluded for this reason were in keeping 
with the respective meta-analytic estimates. Some studies did not report on insignificant results, 
which may have led to publication bias. Failure to quantify follow-up and missing data has not 
allowed us to adequately assess the risk of attrition bias and sampling bias in some studies. Many 
studies excluded erectile dysfunction from the definition of MSA onset whilst some studies excluded 
all autonomic symptoms, which may have overestimated mean age at onset and thus underestimated 
disease duration. Similarly, several prognostic factors such as severe dysautonomia were not 
sufficiently well defined. Nonetheless, in view of the low statistical heterogeneity in most meta-
analyses it is likely that bias arising from retrospective data collection, attrition bias and variations in 
the definition of MSA onset has not substantially influenced the review outcomes.  
Limitations of the review methodology include its restriction to articles published in English, French 
or German and the low specificity of the search strategy, which increases the risk of missing relevant 
studies. The presence of reporting bias cannot be excluded given the limitations of funnel plots where 
several prognostic factors are reported by individual studies.  
 
CONCLUSION 
The present review is the first to summarise, synthesise and contrast evidence on prognostic factors in 
patients with PSP and MSA and it identified several clinical variables that were strongly associated 
with survival (table 1). Results on most prognostic factors were consistent across methodologically 
diverse studies, including both clinical and post-mortem studies. However, the lack of commonality of 
prognostic factors investigated is a significant limitation.  
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FIGURE LEGENDS 
 
Fig 1. Flow chart of study selection process 
 
Fig 2. Line graph (black and white) showing cumulative survival of PSP patients extracted from 
Kaplan-Meier curves of individual studies. Each line represents one study. Post-mortem studies are 
marked with a star. PSP = progressive supranuclear palsy 
 
Fig 3. Line graph (black and white) showing cumulative survival of MSA patients extracted from 
Kaplan-Meier curves of individual studies. Each line represents one study. Post-mortem studies are 
marked with a star. MSA = multiple system atrophy 
 
Fig 4. Forest plot comparing survival between male and female patients 
 
Fig 5. Forest plot comparing survival between MSA-P and MSA-C patients. MSA-C = multiple 
system atrophy cerebellar subtype; MSA-P = multiple system atrophy parkinsonism subtype  
 
Fig 6. Forest plot comparing survival between PSP-RS and PSP-P patients. PSP-P = progressive 
supranuclear palsy parkinsonism subtype; PSP-RS = progressive supranuclear palsy Richardson’s 
subtype 
 
Fig 7. Forest plot comparing survival between patients experiencing early falls (EF) and patients not 
experiencing early falls (no EF) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
